Characterization of the extent of a large outbreak of Legionnaires’ disease by serological assays

BMC Infectious Diseases

Jetmund Ringstad³  Eivind Ragnhildstveit²  Ingeborg S Aaberge¹  Karin Bolstad¹  Anita Kanestrøm²  Elisabeth Wedege¹  Øystein Simonsen³ 

[1] Department of Bacteriology and Immunology, Division of Infectious Disease Control, Norwegian Institute of Public Health, Oslo, Norway;Department of Clinical Microbiology, Østfold Hospital Trust, Fredrikstad, Norway;Department of Medicine, Østfold Hospital Trust, Fredrikstad, Norway

关键词: Community-acquired pneumonia;    Serological assays;    Outbreak;    Legionella pneumophila;   

Others  :  1173921
DOI  :  10.1186/s12879-015-0903-2

 received in 2014-07-09, accepted in 2015-03-13,  发布年份 2015

【 摘 要 】

Background

In May 2005, a long-distance outbreak of Legionnaires’ disease (LD) caused by Legionella pneumophila serogroup 1 occurred in south-east Norway. The initial outbreak investigation without serology identified 56 laboratory-confirmed LD cases of whom 10 died. However, 116 patients with community-acquired pneumonia might belong to the outbreak based on epidemiological investigations, but acute laboratory tests other than serology were negative or not performed. To assess the true extent of the outbreak, we evaluated two serological assays in order to reclassify the 116 patients with indeterminate case status.

Methods

Two polyvalent antibody tests, a serogroup 1–6 immunofluorescence assay (IFA) and a serogroup 1–7 enzyme-linked immunosorbent assay (ELISA) were used. They were evaluated with cases defined as culture- or urinary antigen positive LD patients (n = 40) and non-cases defined as confirmed non-LD patients (n = 39) and healthy control subjects (n = 62). The 116 patients, who were negative in culture, polymerase chain reaction and/or urinary antigen tests, were analysed by the same serological assays. Antibodies to the outbreak strain were determined by immunoblotting.

Results

In the evaluation study, the sensitivity and specificity of a ≥4-fold IFA titre change was 38% and 100%, respectively, with corresponding values of 30% and 99% for seroconversion in ELISA. A single high positive IFA titre yielded sensitivity and specificity of 73% and 97%, respectively, with corresponding values of 68% and 96% for a single high immunoglobulin (Ig) G and/or IgM in ELISA.

Based on this evaluation, the following serological testing identified 47 more LD cases, and the outbreak thus comprised 103 cases with a case fatality rate of 10%. About the same proportion (70%) of the urinary antigen positive and negative LD cases had antibodies to the serogroup-specific lipopolysaccharide of the outbreak strain. In addition to the 103 LD cases, Legionella infection could not be verified or excluded in 32 patients based on epidemiology and/or lack of microbiological sampling.

Conclusions

The acute-phase tests (culture, polymerase chain reaction, and urinary antigen) identified less than 55% of the 103 patients in this outbreak. Serological testing thus remains an important supplement for diagnosis of LD and for determination of outbreak cases.

【 授权许可】

   
2015 Simonsen et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Norwegian Surveillance System for Communicable Diseases (MSIS). [http://www.msis.no]
• [2]Ricketts KD, Joseph CA: European Working Group for Legionella Infections: Legionnaires disease’ in Europe: 2005–2006. Euro Surveill 2007, 12:E7-8.
• [3]Garasen H, Sagvik E, Kvendbo JF, Lian A, Jacobsen T, Nylenna M: Legionella in Trondheim, Norway – determining sources of contagion and tracing risk environments. Tidsskr Nor Laegeforen 2005, 125:1791-3.
• [4]Marston BJ, Plouffe JF, File TM Jr, Hackman BA, Salstrom SJ, Lipman HB, et al.: Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance Study in Ohio. The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997, 157:1709-18.
• [5]Bohte R, van Furth R, van den Broek PJ: Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995, 50:543-7.
• [6]von Baum H, Ewig S, Marre R, Suttorp N, Gonschior S, Welte T, et al.: Community-acquired Legionella pneumonia: new insights from the German competence network for community-acquired pneumonia. Clin Infect Dis 2008, 46:1356-64.
• [7]Macfarlane JT, Finch RG, Ward MJ, Macrae AD: Hospital study of adult community-acquired pneumonia. Lancet 1982, 320:255-8.
• [8]Benin AL, Benson RF, Besser RE: Trends in Legionnaires disease, 1980–1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 2002, 35:1039-46.
• [9]Yu VL, Plouffe JF, Pastoris MC, Stout JE, Schousboe M, Widmer A, et al.: Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 2002, 186:127-8.
• [10]Maurin M, Hammer L, Gestin B, Timsit JF, Rogeaux O, Delavena F, et al.: Quantitative real-time PCR tests for diagnostic and prognostic purposes in cases of legionellosis. Clin Microbiol Infect 2010, 16:379-84.
• [11]Carratalà J, Garcia-Vidal C: An update on Legionella. Curr Opin Infect Dis 2010, 23:152-7.
• [12]Yzerman EP, den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M: Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires’ disease in The Netherlands. J Clin Microbiol 2002, 40:3232-6.
• [13]Helbig JH, Uldum SA, Bernander S, Luck PC, Wewalka G, Abraham B, et al.: Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial Legionnaires’ disease. J Clin Microbiol 2003, 41:838-40.
• [14]Shimada T, Noguchi Y, Jackson JL, Miyashita J, Hayashino Y, Kamiya T, et al.: Systematic review and metaanalysis: urinary antigen tests for Legionellosis. Chest 2009, 136:1576-85.
• [15]Wedege E, Bolstad K, Borgen K, Fritzsonn E, Caugant DA: Molecular characterization of clinical and environmental isolates of Legionella pneumophila in Norway, 2001–2008. Scand J Infect Dis 2013, 45:59-64.
• [16]Nygard K, Werner-Johansen O, Ronsen S, Caugant DA, Simonsen O, Kanestrom A, et al.: An outbreak of Legionnaires disease caused by long-distance spread from an industrial air scrubber in Sarpsborg, Norway. Clin Infect Dis 2008, 46:61-9.
• [17]Olsen JS, Aarskaug T, Thrane I, Pourcel C, Ask E, Johansen G, et al.: Alternative routes for dissemination of Legionella pneumophila causing three outbreaks in Norway. Environ Sci Technol 2010, 44:8712-7.
• [18]Yzerman EP, den Boer JW, Lettinga KD, Schel AJ, Schellekens J, Peeters M: Sensitivity of three serum antibody tests in a large outbreak of Legionnaires’ disease in the Netherlands. J Med Microbiol 2006, 55:561-6.
• [19]Virion\Serion: Serion ELISA classic. Legionella pneumophila 1–7 IgG/IgM. Instructions. [http://www.virion-serion.de/download/gebrauchsanweisung/legionella_pneumophila/IFU-Legionella-EN-ES-GR-PT-CZ.pdf]
• [20]European Centre for Disease Prevention and Control: EU case definition. [http://ecdc.europa.eu/en/activities/surveillance/ELDSNet/Pages/EU%20case%20definition.aspx]
• [21]Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al.: Defining community-acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003, 58:377-82.
• [22]Ciesielski CA, Blaser MJ, Wang WL: Serogroup specificity of Legionella pneumophila is related to lipopolysaccharide characteristics. Infect Immun 1986, 51:397-404.
• [23]Wedege E, Bergdal T, Bolstad K, Caugant DA, Efskind J, Heier HE, et al.: Seroepidemiological study after a long-distance industrial outbreak of Legionnaires’ disease. Clin Vaccine Immunol 2009, 16:528-34.
• [24]Hitchcock PJ, Brown TM: Morphological heterogeneity among Salmonella lipopolysaccharide chemotypes in silver-stained polyacrylamide gels. J Bacteriol 1983, 154:269-77.
• [25]Tsai CM, Frasch CE: A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal Biochem 1982, 119:115-9.
• [26]Helbig JH, Bernander S, Castellani Pastoris M, Etienne J, Gaia V, Lauwers S, et al.: Pan-European study on culture-proven Legionnaires’ disease: distribution of Legionella pneumophila serogroups and monoclonal subgroups. Eur J Clin Microbiol Infect Dis 2002, 21:710-6.
• [27]Open Source Epidemiologic Statistics for Public Health, Version 2.3. [http://www.openepi.com]
• [28]Rojas A, Navarro MD, Fornés FE, Serra E, Simarro E, Rojas J, et al.: Value of serological testing for diagnosis of legionellosis in outbreak patients. J Clin Microbiol 2005, 43:4022-5.
• [29]Hugosson A, Hjorth M, Bernander S, Claesson BE, Johansson A, Larsson H, et al.: A community outbreak of Legionnaires’ disease from an industrial cooling tower: assessment of clinical features and diagnostic procedures. Scand J Infect Dis 2007, 39:217-24.
• [30]Svarrer CW, Luck C, Elverdal PL, Uldum SA: Immunochromatic kits Xpect Legionella and BinaxNOW Legionella for detection of Legionella pneumophila urinary antigen have low sensitivities for the diagnosis of Legionnaires’ disease. J Med Microbiol 2012, 61:213-7.
• [31]Kallings I, Nordstrom K: The pattern of immunoglobulins with special reference to IgM in Legionnaires’ disease patients during a 2 year follow-up period. Zentralbl Bakteriol Mikrobiol Hyg A 1983, 255:27-32.
• [32]De Ory F, Guisasola ME, Eiros JM: Detection of Chlamydophila pneumoniae IgG in paired serum samples: comparison of serological techniques in pneumonia cases. APMIS 2006, 114:279-84.
• [33]Talkington DF, Shott S, Fallon MT, Schwartz SB, Thacker WL: Analysis of eight commercial enzyme immunoassay tests for detection of antibodies to Mycoplasma pneumoniae in human serum. Clin Diagn Lab Immunol 2004, 11:862-7.
• [34]Lück P, Helbig J, Schuppler M: Epidemiology and laboratory diagnosis of Legionella infections. J Lab Med 2002, 26:174-82.
• [35]Jurgens D, Fehrenbach FJ: Cross-reacting lipopolysaccharide antigens in Legionella pneumophila serogroups 1 to 14. Infect Immun 1995, 63:2180-4.
• [36]Nolte FS, Conlin CA: Major outer membrane protein of Legionella pneumophila carries a species-specific epitope. J Clin Microbiol 1986, 23:643-6.
• [37]Lattimer GL, Rhodes LV 3rd, Salventi JS, Galgon JP, Stonebraker V, Boley S, et al.: The Philadelphia epidemic of Legionnaire’s disease: clinical, pulmonary, and serologic findings two years later. Ann Intern Med 1979, 90:522-6.
• [38]Jonkers RE, Lettinga KD, Pels Rijcken TH, Prins JM, Roos CM, van Delden OM, et al.: Abnormal radiological findings and a decreased carbon monoxide transfer factor can persist long after the acute phase of Legionella pneumophila pneumonia. Clin Infect Dis 2004, 38:605-11.
• [39]Lettinga KD, Verbon A, Nieuwkerk PT, Jonkers RE, Gersons BP, Prins JM, et al.: Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of Legionnaires disease. Clin Infect Dis 2002, 35:11-7.